Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

DMPI $1.35 0.1800 +15.38%
GHDX $27.40 2.7500 +11.16%
XLRN $30.19 2.6900 +9.78%
MTP $4.72 0.3000 +6.79%
BPTH $2.64 0.1300 +5.18%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

IDRA $1.34 -0.1500 -10.07%
BCRX $2.73 -0.2700 -9.00%
CLDX $3.49 -0.3400 -8.88%
FBIO $2.92 -0.2600 -8.18%
SPPI $6.40 -0.5600 -8.05%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

Exclusive: Pfizer Approaches Medivation About Potential Takeover - Sources

(Reuters) May 4, 2016 - Pfizer Inc has approached U.S. cancer drug maker Medivation Inc to express interest in an acquisition, raising the possibility of a bid rivaling a $9.3 billion offer by Sanofi SA, people familiar with the matter said on Tuesday.
read article 



FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For BLINCYTO® (Blinatumomab)

(StreetInsider) May 3, 2016 - Acceptance reinforces significant unmet need for difficult-to-treat type of pediatric acute lymphoblastic leukemia.
read article 



FDA Grants Priority Review for Lilly's Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma

(Eli Lilly) May 4, 2016 - Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the biologics license application (BLA) for olaratumab, a PDGFRa antagonist, in combination with doxorubicin, for the potential treatment of people with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery.
read corporate press release 



Now It's Pfizer That Wants to Buy Cancer Drug Maker Medivation

(Fortune) May 4, 2016 - Pfizer has approached U.S. cancer drug maker Medivation to express interest in an acquisition, raising the possibility of a bid rivaling a $9.3 billion offer by Sanofi, people familiar with the matter said on Tuesday.
read article 



Biogen to Spin Off Hemophilia Drug Business Into A Public Company

(CNBC/Reuters) May 3, 2016 - Drugmaker Biogen said on Tuesday it would spin off its hemophilia drug business as a publicly traded company in a tax-free transaction, leaving the drugmaker to focus on developing drugs for neurodegenerative diseases.
read article 



CMS Finalizes Quality Measures In Support Of MACRA

(Healthcare Finance) May 2, 2016 - The Centers for Medicare and Medicaid Services on Monday released its finalized Quality Measure Development Plan to support the recently-released Merit-based Incentive Payment System and Advanced Alternative Payment Models.
read article 



For Hospitals, Prestige Leads To Profits

(Kaiser Health News) May 2, 2016 - When it comes to hospitals, which benefit most from high health care prices? It may sound counter-intuitive, but a group of not-for-profit hospitals appear to be among those doing the best business.
read article 



A Controversial New Demonstration In Medicare: Potential Implications For Physician-Administered Drugs

(Health Affairs) May 3, 2016 - According to an August 2015 survey, 72 percent of Americans find drug costs unreasonable, with 83 percent believing that the federal government should be able to negotiate prices for Medicare.
read article 



Exact Sciences Makes National TV Ad Push to Boost Cologuard Sales

(Xconomy Wisconsin) May 3, 2016 - Exact Sciences plans to launch a national TV advertising campaign in an important test of the appeal of Cologuard, its diagnostic product for colorectal cancer that requires patients to ship samples of their stool to a lab for testing.
read article 



IMS Health to Buy Quintiles in $9 Billion Pharma Data Deal

(Bloomberg) May 3, 2016 - IMS Health Holdings Inc. will buy Quintiles Transnational Holdings Inc. in an all-stock transaction for about $9 billion, bringing together two of the biggest providers of data and services for the pharmaceutical industry.
read article 



NW Bio Announces Operations Updates

(Baltimore Business Journal) May 2, 2016 - Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today an operations update in regard to its Phase I and II Trials, Scientific Advisory Board and Nasdaq compliance.
read article 



Well Water a Suspected Cause of Bladder Cancer in New England

(Drugs.com/HealthDay News) May 2, 2016 - Arsenic in drinking water from private wells may explain the elevated bladder cancer risk among people in three New England states, a new study suggests.
read article 



Cancer Patient, Facility Suing Blue Cross Blue Shield For Denying Treatment

(KFOR-TV/NBC, Ch. 4 [Oklahoma City, OK]) May 2, 2016 - An Oklahoma City cancer treatment facility is taking on a well-known health insurance company, claiming the company interfered with patient care.
read article 



PCORI Puts $44 Million Toward Cancer, PTSD, Care Disparities Research

(Healthcare IT News) May 3, 2016 - The Patient-Centered Outcomes Research Institute has approved $44.4 million to fund 21 new patient-centered comparative clinical effectiveness studies.
read article 



Viewpoints: Your Daily 'Miracle Cure' for Cancer

(Medscape Oncology) May 2, 2016 - Dr Jack West discusses the harm caused by hyperbole in news reports about cancer research, and the steps oncologists can take to prevent it.
read article (free registration required) 



What They Are Saying: Immunotherapy Is Transforming Cancer Care

(PhRMA/The Catalyst) May 2, 2016 - New and innovative immunotherapy medicines developed by America’s biopharmaceutical research companies are transforming how we fight cancer and are providing newfound hope to patients.
read article 



Kite Pharma Announces FDA Orphan Drug Designations for KTE-C19 in Five Additional Indications

(NASDAQ) May 2, 2016 - All hematological malignancies targeted by KTE-C19 development now covered by Orphan Drug Designations in U.S. and EU.
read article 



Jiangsu Hengrui Medicine Enters into Agreement with The University of Texas MD Anderson Cancer Center to Advance Immunotherapy and Precision Medicine for Cancer Treatment

(PRNewswire) May 3, 2016 - Jiangsu Hengrui Medicine Co., Ltd and The University of Texas MD Anderson Cancer Center (MD Anderson) have entered into a research agreement to advance cancer treatment.
read press release 



Oncodesign and Ipsen Enter into a Strategic Partnership in Oncology and Oncodesign Joins Ipsen’s Paris-Saclay Campus

(Yahoo! Finance) May 3, 2016 - Oncodesign is becoming a strategic partner for Ipsen in pre-clinical pharmacology for its oncology research programs; Oncodesign teams are moving to Ipsen’s private open innovation campus in Paris-Saclay.
read article 



Colombia Moves To Override Patent For Novartis Cancer Drug

(STAT/Pharmalot) May 2, 2016 - The Colombian health ministry plans to override a patent that Novartis holds on its widely used Gleevec cancer treatment, the latest clash between the pharmaceutical industry and some governments over intellectual property and access to medicines.
read article 



Genentech Highlights Personalized Medicines and Cancer Immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

(Genentech) May 2, 2016 - 19 Genentech medicines are included in more than 200 abstracts during ASCO 2016; new results for cancer immunotherapy atezolizumab in bladder cancer and other cancer types; early results for atezolizumab in combination with targeted medicines and the investigational cancer immunotherapy MOXR0916, an OX40 agonist; superiority results from Phase III study comparing Alecensa® (alectinib) to crizotinib.
read corporate press release 



Psychotherapy Video Chats May Help With ‘Chemo Brain’

(Reuters Health) May 3, 2016 – Memory problems that plague cancer survivors after chemotherapy can sometimes be improved with a type of psychotherapy delivered by video chat, a new study suggests.
read article 



Team Identifies New Function Of Genes Linked To Fanconi Anemia And Certain Types Of Cancer

(UT Southwestern) May 2, 2016 - Researchers from UT Southwestern Medical Center have identified an important new function of genes in the Fanconi anemia pathway – a finding that could have implications for development of new therapies to treat this disorder and some cancers.
read press release 



Cancer-like Mutations Prevalent In Apparently Healthy Group

(HSNewsBeat/UW Health Sciences) May 2, 2016 - In a study of 36 women – 16 diagnosed with ovarian cancer and a control group of 20 with no cancer diagnosis – nearly all of the women were found to carry cancer-associated gene mutations.
read article 



Scientists Double Number Of Known Genetic Risk Factors For Endometrial Cancer

(University of Cambridge [UK]) May 3, 2016 - An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
read article